Drägerwerk stock gains after stronger margins and outlook upgrade

Drägerwerk stock (ISIN DE0005550636) recently traded at around EUR 110 in Xetra trading on September 8, 2026, after the Lübeck-based medical and safety technology group reported a marked improvement in its Q2 2026 margins compared with the prior year quarter. As of early September 2026, investors are focusing on the company’s upgraded profitability outlook and the emerging turnaround story.

Margins improve clearly in Q2 2026

According to an analysis by Boerse Online published on September 10, 2026, Drägerwerk generated currency-adjusted revenue of EUR 847.3 million in the second quarter of 2026, an increase of 8.5 percent versus the prior-year period. In the same quarter, the group’s EBIT margin improved from 2.6 percent in Q2 2025 to 5.4 percent in Q2 2026, underlining the success of cost-saving measures and a more profitable product mix. The article also notes that management raised its guidance for the full-year 2026 EBIT margin after further customs refund income, signaling greater confidence in sustained margin improvement.

The medtech segment showed particularly strong momentum in Q2 2026. As reported by Boerse Online, segment EBIT swung from a loss of EUR 5.9 million in Q2 2025 to a profit of EUR 4.3 million in Q2 2026. Segment revenue in medtech increased currency-adjusted by 9.7 percent to EUR 479.8 million over the same period, helped by higher-priced ventilators and anesthesia machines, lower costs and growing service business. For investors, the quantified turnaround in this core segment is central to the investment case.

Analyst support and long-term targets

Analyst coverage has turned more constructive as margins improve. Drägerwerk’s own investor-relations overview lists mwb research with a Buy recommendation on the stock as of August 2026, alongside a Hold rating from Metzler in July 2026, according to the company’s Dräger Share page. In a more detailed note, mwb research recently raised its price target for Drägerwerk, citing increased confidence in margin trends, as reported on August 31, 2026 by MarketScreener. The MarketScreener report notes that mwb research lifted its target price for the stock in light of improving margins and a more favorable risk profile.

The same MarketScreener overview highlights that Drägerwerk shares on Cboe Europe were quoted at EUR 65.30 as of September 9, 2026, showing a year-to-date performance of plus 29.05 percent. As MarketScreener reports, Drägerwerk has also set medium-term targets for 2030 that are seen as reducing mid-term risk, aligning its profitability ambitions with a clear strategic roadmap. For shareholders, the combination of near-term margin improvement and longer-term targets offers a more transparent path to value creation, while continued execution remains a key risk.

Stock levels and technical context

On the index level, Drägerwerk participates in the TecDAX and SDAX, and recent trading data show the stock holding firm after its fundamental news. A TecDAX component overview from Finanzen.at shows Drägerwerk preferred shares at a last price of EUR 110.20 on September 8, 2026, slightly below the prior close of EUR 111.00, corresponding to a day-on-day decline of 0.72 percent. In parallel, a separate SDAX trading wrap from Finanzen.ch dated September 9, 2026 lists Drägerwerk among the stronger SDAX constituents, with the stock up 0.73 percent to EUR 111.00 in that session.

A peer-group technical overview from Boerse Social on September 10, 2026 notes that Drägerwerk shares were around 24.62 percent above their 200-day moving average, underlining a robust medium-term uptrend compared with German mid-cap peers. For investors who follow technical signals, the distance to the 200-day line complements the fundamental turnaround figures and suggests that the improved earnings profile is already reflected in the market’s pricing to a significant extent.

Drägerwerk stock price as of the last close

Based on the TecDAX component data from Finanzen.at, Drägerwerk’s primary listing on Xetra shows a last recorded close at EUR 110.20 on September 8, 2026, after a prior close of EUR 111.00, implying a modest single-day decline of 0.72 percent at that point. This price level places the stock well above its longer-term average as indicated by the peer-group analysis, while investors continue to weigh the upside from improved margins against execution risks in delivering on the raised 2026 EBIT-margin guidance.

More news and analyses on Drägerwerk stock